The estimated Net Worth of Preetam Shah is at least $733 millier dollars as of 11 March 2024. Preetam Shah owns over 18,931 units of Brainstorm Cell Therapeutics stock worth over $63,619 and over the last 5 years he sold BCLI stock worth over $22,855. In addition, he makes $646,892 as Chief Financial Officer, Executive Vice President et Treasurer at Brainstorm Cell Therapeutics.
Preetam has made over 5 trades of the Brainstorm Cell Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 18,931 units of BCLI stock worth $12,684 on 11 March 2024.
The largest trade he's ever made was exercising 50,000 units of Brainstorm Cell Therapeutics stock on 15 September 2022 worth over $14,000. On average, Preetam trades about 9,744 units every 140 days since 2019. As of 11 March 2024 he still owns at least 227,210 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Preetam Shah stock trades at the bottom of the page.
Dr. Preetam Shah Ph.D. serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. He served as Director, Healthcare Investment Banking at Barclays Capital Plc. since June 2016. He has also served as Vice President, Healthcare Investment Banking at Canaccord Genuity Inc. from 2013 to 2016. Dr. Shah founded Saisarva LLC. and was a financial consultant from 2010-2013 for healthcare-focused private equity firms, hedge funds, and global pharmaceutical companies. From 2006-2009, Dr. Shah served as Vice President, U.S. Operations and Investments at Reliance Capital USA Ventures LLC, an affiliate of Reliance ADA Group Companies. Dr. Shah completed his post-doctoral fellowship in Infectious Diseases from Stanford University School of Medicine. He holds a Ph.D. in Microbiology from the University of Mississippi Medical Center and a M.B.A. in Finance from the Wharton School, University of Pennsylvania.
As the Chief Financial Officer, Executive Vice President et Treasurer of Brainstorm Cell Therapeutics, the total compensation of Preetam Shah at Brainstorm Cell Therapeutics is $646,892. There are 5 executives at Brainstorm Cell Therapeutics getting paid more, with Chaim Lebovits having the highest compensation of $1,639,680.
Preetam Shah is 47, he's been the Chief Financial Officer, Executive Vice President et Treasurer of Brainstorm Cell Therapeutics since 2019. There are 12 older and 5 younger executives at Brainstorm Cell Therapeutics. The oldest executive at Brainstorm Cell Therapeutics, Inc. is Malcolm Taub, 74, who is the Independent Director.
Preetam's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger et International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: